All News

2061 articles, sorted by publication time.

Clinical Trials · global

More evidence for fully subcutaneous treatment of Crohn’s disease: Phase 3 Skyrizi trial reports endoscopic remission results

Subcutaneous administration for both induction and maintenance treatment could allow more flexible treatment scheduling. New AFFIRM data show that patients who had achieved a clinical response during induction had a higher rate of endoscopic remission at Week 24 than those receiving placebo; this administration approach remains under review by US and European regulators.